<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01072383</url>
  </required_header>
  <id_info>
    <org_study_id>973</org_study_id>
    <nct_id>NCT01072383</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis</brief_title>
  <official_title>A Randomized, Placebo-controlled, Double-blind, Multicentre, Multiple Dose, Cohort Study With Escalating Doses to Evaluate the Safety and Efficacy of the Humanized Monoclonal Antibody BT061 Administered to Patients With Moderate to Severe Chronic Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotest</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase II clinical study is to test safety and efficacy of BT061 against psoriasis given
      as repeated doses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are enrolled into escalating dose levels. Improvement of PASI, physician's global
      assessment and itching score is evaluated after administration of BT061 or placebo. Safety
      data are assessed by an independent data and safety monitoring board (DSMB).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in PASI score (Psoriasis Area and Severity Index) , as compared to PASI at baseline visit,</measure>
    <time_frame>weekly during treatment, then 1 week, 1 month and 3 months after last dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose group with the highest number of responders (PASI score improvement)</measure>
    <time_frame>weekly during treatment, then 1 week, 1 month and 3 months after last dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PGA (Physician's global assessment)</measure>
    <time_frame>weekly during treatment, then 1 week, 1 month and 3 months after last dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Itching score</measure>
    <time_frame>weekly during treatment, then 1 week, 1 month and 3 months after last dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLQI (dermatology life quality index)</measure>
    <time_frame>weekly during treatment, then 1 week, 1 month and 3 months after last dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination</measure>
    <time_frame>weekly during treatment, then 1 week, 1 month and 3 months after last dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differential white blood cell count</measure>
    <time_frame>weekly during treatment, then 1 week, 1 month and 3 months after last dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine profile</measure>
    <time_frame>weekly during treatment, then 1 week after last dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>BT061</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receiving BT061 (active compound)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>receiving a placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BT061</intervention_name>
    <description>administration of BT061 either intravenous or subcutaneous</description>
    <arm_group_label>BT061</arm_group_label>
    <other_name>SC or IV administration of BT061 or placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo treatment</intervention_name>
    <description>administration of the end formulation buffer of BT061 without active ingredient, either subcutaneous or intravenous</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>SC or IV administration of BT061 or placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients with moderate, moderate to severe or severe chronic plaque
             psoriasis diagnosed ≥ 12 months prior to Screening.

          -  BSA (Body surface area) involvement &gt; 10% for more than 6 months.

          -  PASI ≥10.

          -  Age ≥ 18 to ≤ 75 years.

          -  Body mass index (BMI) of 18-30 kg/m2 with a body weight between 50 and 130 kg.

        Exclusion Criteria:

          -  Erythrodermic, guttate or palmar pustular psoriasis (mixed forms may be admissible if
             chronic plaque psoriasis clearly remains the predominant diagnosis

          -  Treatment with a biological within less than 30 days or within less than 5 half-lives
             of the respective compound prior to administration of BT061/placebo.

          -  Serious local (e.g. abscess) or systemic infection (e.g. pneumonia, septicaemia)
             within 3 months prior to the administration of BT061 or placebo.

          -  Presence or history of clinically significant immune deficiency or autoimmune disease
             (except psoriasis).

          -  Positive diagnosis for acute or chronic infections (i.e. Hepatitis C Virus [HCV],
             Hepatitis B Virus [HBV], Human Immunodeficiency Virus [HIV]) at Screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lajos Kemény, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Szegedi Tudományegyetem (Study site)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermatologic Clinic</name>
      <address>
        <city>Ostrava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologic Clinic I</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologic Clinic Prague III</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologic Clinic Prague II</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologic Clinic</name>
      <address>
        <city>Ústí nad Labem</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologic Clinic</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologic Clinic</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologic Clinic</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologic Clinic</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologic Clinic</name>
      <address>
        <city>Szikszo</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologic Clinic</name>
      <address>
        <city>Szolnok</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologic Clinic</name>
      <address>
        <city>Szombathely</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologic Clinic</name>
      <address>
        <city>Veszprém</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Hungary</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2010</study_first_submitted>
  <study_first_submitted_qc>February 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2010</study_first_posted>
  <last_update_submitted>March 12, 2012</last_update_submitted>
  <last_update_submitted_qc>March 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic plaque psoriasis</keyword>
  <keyword>psoriasis vulgaris</keyword>
  <keyword>autoimmune disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

